Cytospire raised £61 million (about $83 million) in a Series A to advance CYT X300, its gamma delta T-cell engager program for solid tumors. The London-based biotech said it plans early testing in EGFR-positive solid tumors including colorectal, head and neck, and non-small-cell lung cancer. The company’s CEO Natalie Mount said gamma delta T cells are already present in the tumor microenvironment and may deliver stronger tumor-selective activity than other T-cell subsets. She also framed CYT X300 as designed to be delivered in a biologic format familiar to large pharma and scalable for broader patient access. Cytospire’s lead program has yet to enter human studies, and the company pointed to participation by Abingworth and a Series A lead led by 4BIO Capital, with additional involvement from Servier’s venture arm.